A new weekly injection for polycythemia vera, a rare chronic blood cancer that causes the body to overproduce red blood cells and thicken the blood, won Food and Drug Administration approval on Friday. The drug is called rusfertide, developed by the biotech company Protagonist Therapeutics. Patients will receive it under the brand name Mimrylo, sold by Takeda, the Japanese pharmaceutical company.
What polycythemia vera does
Here is what the disease actually does. The body keeps producing red blood cells past the point where it should stop, and those extra cells accumulate in the bloodstream. Blood carrying more cells than it needs becomes physically thicker. Thicker blood is harder to move and more prone to clotting, and the risks that follow are the ones the clearance addresses: heart attacks, strokes, and dangerous blood clots.
Polycythemia vera is slow-growing, which can make it deceptive. Symptoms may remain manageable for years while the cardiovascular risk keeps building underneath. The disease is also chronic, meaning it does not resolve on its own. Patients manage it across years rather than completing a single course of treatment. And the condition is rare: the population living with this diagnosis is small.
What was cleared and who makes it
What the FDA specifically approved: rusfertide, administered by injection once a week, for adults with polycythemia vera. The commercial name patients will encounter is Mimrylo.
Protagonist Therapeutics, the biotech company, developed the drug. Takeda, the Japanese pharmaceutical company, takes on the commercial side: manufacturing Mimrylo and distributing it to patients. The two companies together cover the distance from a regulatory decision to a treatment that reaches a clinic.
The clearance came Friday. For patients carrying a cancer that their own body keeps driving through unchecked red blood cell production, a weekly injectable option now has federal approval behind it.